Chong Kun Dang Pharmaceutical Capital Reinvestment Ratio
Chong Kun Dang Pharmaceutical capital reinvestment ratio. Chong Kun Dang Pharmaceutical (185750) has a Capital Reinvestment Ratio of 6.04x as of March 2026, meaning it reinvests 6% of its operating cash flow (₩12.32 Billion) in capital expenditures (₩74.34 Billion). Check 185750 capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of Chong Kun Dang Pharmaceutical (2016–2025)
Capital reinvestment ratio of Chong Kun Dang Pharmaceutical from 2016 to 2025. This chart tracks Chong Kun Dang Pharmaceutical's Capital Reinvestment Ratio across 10 annual periods. Also explore Chong Kun Dang Pharmaceutical equity growth rate to track the company's year-over-year net asset growth rate.
Chong Kun Dang Pharmaceutical Capital Reinvestment Ratio by Year (2016–2025)
Chong Kun Dang Pharmaceutical capital reinvestment ratio by year from 2016 to 2025. For the full cash flow conversion analysis, see 185750 cash flow conversion.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 2.66x | ₩67.36 Billion | ₩179.13 Billion | ▲ +158.6% |
| 2024 | 1.03x | ₩64.29 Billion | ₩66.10 Billion | ▲ +375.4% |
| 2023 | 0.22x | ₩318.16 Billion | ₩68.81 Billion | ▼ -67.4% |
| 2022 | 0.66x | ₩67.73 Billion | ₩44.90 Billion | ▼ -82.3% |
| 2021 | 3.74x | ₩12.90 Billion | ₩48.24 Billion | ▲ +1095.0% |
| 2020 | 0.31x | ₩104.32 Billion | ₩32.64 Billion | ▲ +10.7% |
| 2019 | 0.28x | ₩77.29 Billion | ₩21.84 Billion | ▼ -45.0% |
| 2018 | 0.51x | ₩42.63 Billion | ₩21.92 Billion | ▲ +112.2% |
| 2017 | 0.24x | ₩81.67 Billion | ₩19.79 Billion | ▼ -64.5% |
| 2016 | 0.68x | ₩57.79 Billion | ₩39.44 Billion | — |